The Long Run with Luke Timmerman Ep181: Claire Mazumdar on a Two-Pronged Attack Against Cancer
8 snips
Jul 1, 2025 In this engaging discussion, Claire Mazumdar, CEO of Bicara Therapeutics, shares insights on developing innovative bifunctional antibodies for cancer treatment. She dives into the promising results of Fiserafusp Alpha for head and neck cancer and the challenges of clinical trials during the pandemic. Claire emphasizes the crucial blend of science and business strategy in biotech, recounts her journey from academia to entrepreneurship, and highlights the importance of support systems in balancing a demanding career and family. This conversation reveals the evolving landscape of cancer treatments!
AI Snips
Chapters
Transcript
Episode notes
Value of Business School for Scientists
- Gain business skills to confidently communicate science and business concepts in biotech.
- Combine scientific knowledge with business understanding to make smarter strategic decisions.
Tumor-Targeted TGF-beta Inhibition
- Targeting TGF-beta specifically within the tumor microenvironment can overcome immune exclusion and resistance.
- The bifunctional EGFR-TGF-beta antibody localizes suppression to tumors, enhancing immune cell infiltration.
Launching Bicara During Pandemic
- Claire Mazumdar started the company Bicara Therapeutics while six months pregnant during the COVID-19 peak in 2020.
- The team quickly adapted to remote work, facing unique challenges in founding and building the company under pandemic conditions.